AVEO Pharmaceuticals (Seite 51)
eröffnet am 11.06.14 13:35:59 von
neuester Beitrag 18.10.22 16:55:22 von
neuester Beitrag 18.10.22 16:55:22 von
Beiträge: 669
ID: 1.195.302
ID: 1.195.302
Aufrufe heute: 0
Gesamt: 74.355
Gesamt: 74.355
Aktive User: 0
ISIN: US0535883070 · WKN: A2P0CL
15,000
USD
+0,07 %
+0,010 USD
Letzter Kurs 20.01.23 NYSE
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,0000 | +25,00 | |
| 56,69 | +20,00 | |
| 0,6400 | +18,52 | |
| 1,1100 | +15,70 | |
| 26,46 | +15,70 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 | |
| 0,7000 | -61,96 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 51.473.919 von sneakee am 12.01.16 16:53:24Also ich sag dies nicht weil ich selber Aktionär bin, aber AVEO ist sowas von unterbewertet bei all den guten Nachrichten der letzten Zeit! Nur die schlechte Börsenstimmung der letzten Tage ist für SmallCaps einfach Gift! Nun sind wir wieder da eo wir vor der EU Partnerschaft waren...
ganz schön viel los auf tradegate heute und recht hoher umsatz und über pari. hats wohl einer recht eilig paar stücke zu haben!!
Zacks Investment Research upgraded shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) from a hold rating to a buy rating in a report issued on Tuesday,Marketbeat.com reports. They currently have $1.50 target price on the biopharmaceutical company’s stock.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) belongs to Healthcare sector. Its weekly performance is -10.32%. On last trading day company shares ended up at $1.13. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) distance from 50-day simple moving average (SMA50) is -38.99%.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) belongs to Healthcare sector. Its weekly performance is -10.32%. On last trading day company shares ended up at $1.13. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) distance from 50-day simple moving average (SMA50) is -38.99%.
Trading Spotlight
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
AVEO Oncology (AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San Francisco.
A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.
AVEO Oncology (AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San Francisco.
A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.
Form 8-K for AVEO PHARMACEUTICALS INC
5-Jan-2016
Results of Operations and Financial Condition, Regulation FD Disclosure,
Item 2.02. Results of Operations and Financial Condition.
Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2015, the Company will disclose as part of its corporate slide presentation presented during upcoming meetings with third parties that it expects to report that it had approximately $34 million in cash, cash equivalents and marketable securities as of December 31, 2015.
The information contained in this Item 2.02 of Form 8-K is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2015 and its results of operations for the three months and year ended December 31, 2015. The audit of the Company's consolidated financial statements for the year ended December 31, 2015 is ongoing and could result in changes to the information set forth above.
The information in this Item 2.02 shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01. Regulation FD.
From time to time, the Company intends to conduct meetings with third parties in which it will present its current corporate slide presentation. A copy of this slide presentation, dated January 5, 2016, is attached as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.
The information in this Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
5-Jan-2016
Results of Operations and Financial Condition, Regulation FD Disclosure,
Item 2.02. Results of Operations and Financial Condition.
Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2015, the Company will disclose as part of its corporate slide presentation presented during upcoming meetings with third parties that it expects to report that it had approximately $34 million in cash, cash equivalents and marketable securities as of December 31, 2015.
The information contained in this Item 2.02 of Form 8-K is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2015 and its results of operations for the three months and year ended December 31, 2015. The audit of the Company's consolidated financial statements for the year ended December 31, 2015 is ongoing and could result in changes to the information set forth above.
The information in this Item 2.02 shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01. Regulation FD.
From time to time, the Company intends to conduct meetings with third parties in which it will present its current corporate slide presentation. A copy of this slide presentation, dated January 5, 2016, is attached as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.
The information in this Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
die steigt dann mit einmal wenns keiner vermutet...
Antwort auf Beitrag Nr.: 51.347.154 von question-mark am 21.12.15 16:25:22Der Kursverfall war mir eh imer ein Rätsel. Vergleicht man den titel mit Morphosys, dann ist die Bewertung um ein vielfaches höher zu setzen. Von den Höchstkursen will ich erst gar nicht träumen 
Durchsuchen
